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Nanotechnology can be defined as the science and 
engineering involved in the design, synthesis, 
characterization and application of materials and devices 
whose smallest functional organization in at least one 
dimension is on the nanometer scale (one-billionth of a 
meter) 1-2. In the past few years nanotechnology has 
grown by leaps and bounds, and this multidisciplinary 
scientific field is undergoing explosive development3-6. It 
can prove to be a boon for human health care, because 
nanoscience and nanotechnologies have a huge potential 
to bring benefits in areas as diverse as drug development, 
water decontamination, and the production of stronger, 
lighter materials. Human health-care nanotechnology 
research can definitely result in immense health benefits. 
The genesis of nanotechnology can be traced to the 
promise of revolutionary advances across medicine. A 
complete list of the potential applications of 
nanotechnology is too vast and diverse to discuss in 
detail, but without doubt, one of the greatest values of 
nanotechnology will be in the development of new and 
effective medical treatments7-10. 
Nanotechnology also providing us with the tools to 
prevent a disease before it attacks the body, like DNA 
vaccine. As far as nanoparticles are concerned, 
development of biodegradable polymeric nanoparticles 
have been a wonderful idea as they can deliver drugs, 
proteins and DNA to a target tissue and are able to 
release drug in a controllable manner irrespective of the 
route of administration11. 
Nanoconstructions could deliver medicines to particular 
targeted site, making possible the more precise treatment. 
Such devices would have a small computer and several 
binding sites to determine the concentration of specific 
molecules in the body, and small amount of poison can 
also be delivered at target site to destroy the selectively 
targeted cells. Similar machines equipped with specific 
„weapons‟ could be used to remove obstructions in the 
blood circulatory system and to kill cancer cells. 
Nanorobots which are operating in the human body, has 
the ability to monitor the level of different compounds as 
well as store related information in its internal memory. 
They could be used to rapidly examine a given tissue; 
this would help in better disease diagnosing 12. 
Nanotechnology-based delivery systems can also protect 
drugs from degradation. These properties can help 
reduce the number of doses required, make treatment a 
better experience and reduce treatment expenses. A 
number of nano-based systems allow delivery of 
insoluble drugs, allowing the use of previously rejected 
drugs or drugs which are difficult to administer e.g. 
paclitaxel. At present these systems are generally used 
for existing, fully developed off-patent drugs, the so- 
called “low-hanging fruit” of nanotechnology-based 
delivery. These technologies include nanoarrays, protein 
arrays, nanopore technology, nanoparticles (NPs) as a 
contrivance in immunoassays and nanosensors, among 
others. Gold NPs and quantum dots (semiconductors) are 
the most widely used, but new materials are becoming 
available as more molecular entities are discovered as 
amenable to nanoscale design and fabrication. Crystal 
materials like those of gallium, phosphate, quartz, and 
ceramic are chosen for their durability and piezoelectric 
properties of developing and retaining an electric 
potential (charge) when subjected to mechanical stress. 
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ABSTRACT: 
Nanotechnology is novel and having full scope of contribution in the field of human health care. Recent advances suggest that 
nanotechnology will have a profound impact on diseases prevention, diagnosis and treatment. It will allow faster drug 
absorption, controlled dose release with minimized side-effects. Nanotechnology plays a crucial role in revolutionizing the 
field of surgery, detection of disease like cancer. Drugs with high toxic potential can be given with a better safety profile with 
the utility of nanotechnology. It is an ideal targeting system should have long circulating time, it should be present at 
appropriate Concentrations at the target site, and it should not lose its activity or therapeutic efficacy while in circulation. Our 
aim is to review the potential applications and various drug delivery system of nanotechnology.  
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Another area of development is nanobiosensors, in which 
antibody- based piezoelectric nanobiosensors are well 
developed. Nanoparticles take advantage of their 
dramatically increased surface area to volume ratio. 
Nanotechnology should not be viewed as a single 
technique that only affects specific areas. It is more of a 
„catch-all‟ term for a science which is benefiting a whole 
array of areas, from the environment, to healthcare, to 
hundreds of commercial products13. Nanotechnology is 
an ideal targeting system should have long circulating 
time, it should be present at appropriate concentrations at 
the target site, and it should not lose its activity or 
therapeutic efficacy while in circulation. Various 
nanosystems, as a result of their larger size, are 
accumulated at higher concentrations than normal drugs. 
In addition, the increased vascular permeability coupled 
with an impaired lymphatic drainage in tumors allows an 
enhanced permeability and retention effect of the the 
tumors or inflamed tissue. Thus, this pathophysiological 
opportunity allows extravasation of the nanosystems and 
their selective localization in the inflamed tissues. The 
tendency of nanosystems to specifically localize in the 
reticuloendothelial system also presents an excellent 
opportunity for passive targeting of drugs to the 
macrophages present in the liver and spleen. Thus, this 
natural system can be used for targeting drugs for 
intracellular infections 14. The therapeutic value of many 
promising drugs for the treatment of various neurological 
disorders is diminished by the presence of the blood-
brain barrier15. The blood-brain barrier is a unique 
membrane that tightly segregates the brain from the 
circulating blood. Thus, drug delivery to this organ is a 
challenge, because the brain benefits from very efficient 
protection. Nanotechnology offers a solution for using 
the numerous chemical entities for treating brain 
disorders that are not clinically useful because of the 
presence of the blood-brain barrier. Nanoparticles can be 
effectively used to deliver relevant drugs to the brain 16. 
Nanotechnology is a new emerging branch of 
technology, which bears high expectations of its 
potential to change the world fundamentally.  Some 
policy makers and technology developers even speak 
about “the Next Industrial Revolution”, which advancing 
nanotechnology is supposed to bring along. However, the 
development of nanotechnology is in such an early state 
that there is not even complete consensus about the 
definition of nanotechnology and its essence. Some 
claim that nanotechnology is a specific area of research 
and it can be defined as a general purpose technology 
(GPT). GPT refers to technologies that have the 
following three characteristics: pervasiveness (has some 
function that is vital to the functioning of a large segment 
of existing or potential products and production 
systems), innovation spawning (fosters new innovations 
that directly or indirectly result from the early major 
invention) and scope for improvement (technology 
improves substantially over time) 17. Others argue that 
nanotechnology is just a new label put on research 
projects in conventional fields of science – such as 
chemistry, physics, biomedical engineering, materials 
science and electrical engineering – to gain more re- 
search funding18. However, there have been also efforts 
to define various terms in the field of nanotechnology, 
and thus build common understanding about the issue. 
Nanotechnology helps us to deliver drug in the form of 
dendrimers, liposomes, nanoshells, emulsions, 
nanotubes, quantum dots etc. for the manipulation of 
various diseases and their metabolic pathway. It is of 
great importance in treatment and diagnosis of cancer19. 
Some of the marketed formulations of nanotechnology 
which have been used for the treatment of various 
diseases are listed in Table 1. 
 
Table 1: List of some marketed formulations 
S.No Name of Drug Brand Name Company Name  Use 
1 Doxorubicin Doxil OrthoBiotech Ovarian tumour 
2 Amphotericin B AmBisome Astellas Pharma US Fungal infection 
3 Paclitaxel Abraxane Abraxis Oncology Non small cell lung cancer 
4 Iron Oxide Combidex/Ferumoxtran AMAG Pharmaceuticals MRI contrast agent 
5 L-Lysine VivaGel Starpharma pty. Ltd. HIV/HSV preventions 
 
ADVANTAGES OF NANOTECHNOLOGYs 
 Qdots that identify the location of cancer cells 
in the body. 
 Nanoparticles that deliver chemotherapy drugs 
directly to cancer cells to minimize damage to healthy 
cells. 
 Nanoshells that concentrate the heat from 
infrared light to destroy cancer cells with minimal 
damage to surrounding healthy cells. 
 Nanotubes used in broken bones to provide a 
structure for new bone material to grow. 
 Nanoparticles that can attach to cells infected 
with various diseases and allow a doctor to identify, in a 
blood sample, the particular disease20-21. 
NANOTECHNOLOGY BASED DRUG DELIVERY 
SYATEM 
There are so many types of drug delivery system used in 
nanotechnology techniques and these systems have 
considerable potential for the treatment of many 
diseases. 
Gold Nanoparticles  
Colloidal gold nanoparticles have been used for a 
relatively long time for the treatment of diseases 
including cancer, rheumatoid arthritis, multiple sclerosis 
and neurodegenerative conditions such as Alzheimer‟s 
disease. The advantages of gold nanoparticles are their 
ease of preparation in a range of sizes, good 
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biocompatibility, easily functionalised and their ability to 
conjugate with other biomolecules without altering their 
biological properties. Gold nanoparticles with diameters 
≤ 50 nm have been shown to cross the BBB. PEGylated 
gold nanoparticles conjugated with TNF (tumour 
necrosis factor) can enter tumour cells through their 
leaky vasculature
22
. Multi-functionalization is the main 
characteristics of nanoparticles. Nanoparticles can be 
integrated with ligands, imaging labels, therapeutic 
agents and other functionalities for specific drug delivery 
and cellular uptake.  
Aryal et al., 2009 was found that Doxorubicin, an 
anticancer drug can conjugate with gold nanoparticles 
and by conjugation there is increase in the potency of 
doxorubicin. So the cytotoxic effect of doxorubicin is 
increased23. Through functionalization gold nanoparticles 
convert poor active drug to high active drug. Thus gold 
nanoparticles have a great contribution in cancer therapy, 
diagnosis of cancerous cell and importance in the therapy 
of HIV24. 
Magnetic Nanoparticles  
Magnetic nanoparticles have become one of the most 
studied and applied nanotechnology in the past few 
years. Applications involving magnetic nanoparticles 
include targeted drug delivery, as contrast agents in 
Magnetic Resonance Imaging (e.g. Feridex), gene 
delivery and cell separation, cell labelling. Iron oxide 
nanoparticles are widely studied due to their 
biodegradable nature, biocompatibility and 
superparamagnetic properties suited for MRI 
applications. Magnetic nanoparticles that can be loaded 
with drugs and still retain their MRI properties have been 
reported. The iron oxide nanoparticles were coated with 
oleic acid and loaded with anticancer agent‟s 
doxorubicin and paclitaxel with a loading efficiency of 
up to 95%25. Industrial applications of magnetic 
nanoparticles cover a broad spectrum such as magnetic 
seals in motors, magnetic inks for bank cheques, 
magnetic recording media and biomedical applications 
such as magnetic resonance contrast media and 
therapeutic agents in cancer treatment 26. 
Ceramic Nanoparticles  
Nanoparticles of silica, titanium, alumina etc. are 
normally classified under the heading ceramic 
nanoparticles. One of the advantages of these particles is 
that their preparation is very simple. They are unaffected 
by changes in pH or temperature. It is possible to 
manipulate many features of these nanoparticles, 
including size, shape, porosity, inertness etc., and they 
can easily be modified to attach different biomolecules. 
Their typical size is around 50 nm. Ceramic 
nanoparticles have been used to encapsulate hydrophobic 
drug molecules, the acid labile model enzyme, 
serratiopeptidase and increase the transfection efficiency 
of DNA (used with a DNA- dendrimer conjugate)27. 
Ceramics have been used in bone tissue engineering due 
to their osteoinductive and biocompatible properties. 
Yamashita et al, 2009 investigated the effects of rough 
and smooth surfaces of ceria stabilized zirconium 
dioxide - another ceramic material that holds promise as 
a dental implant material on the growth and attachment 
of murine osteoblast-like MC3T3-E1 cells and compared 
their results to those obtained with the same cell line 
grown on pure alumina oxide and titanium28. 
Liposomes 
Liposomes discovered in mid 1960s were the original 
models of nanoscaled drug delivery devices. They are 
spherical nanoparticles made of lipid bilayer membranes 
with an aqueous interior but can be unilamellar with a 
single lamella of membrane or multilamellar with 
multiple membranes. They can be used as effective drug 
delivery systems. Cancer chemotherapeutic drugs and 
other toxic drugs like amphotericin and hamycin, when 
used as liposomal drugs produce much better efficacy 
and safety as compared to conventional preparations. 
These liposomes can be loaded with drugs either in the 
aqueous compartment or in the lipid membrane. Usually 
water soluble drugs are loaded in aqueous compartment 
and lipid soluble drugs are incorporated in the liposomal
 membrane29. The limitation of liposome is its 
rapid degradation and clearance by the liver 
macrophages30, thus reducing the duration of action of 
the drug it carries. Other ways of prolonging the 
circulation time of liposomes are incorporation of 
substance like cholesterol31, polyvinyl pyrollidone 
polyacrylamide lipids32 and high transition temperature 
phospholipids distearoyl phosphatidylcholine33.  
Targeting of liposomal drugs: Liposomes can be targeted 
to specific organ or tissue by passive as well as active 
methods. As the liposomal drug acts minimally on other 
tissues, the safety profile is better than non-liposomal 
drug. The vascularity in tumour tissue is poorly 
organized and significant leak occurs from blood vessel 
in the tumour tissue. The liposomal drugs get 
accumulated in the tumour tissue passively and produce 
enhanced effects. Active targeting of the drug can be 
achieved by using immunoliposomes and ligand directed 
liposomes34.  
Niosomes 
 Niosomes are non-ionic surfactant vesicles with a 
similar structure to liposomes. They can encapsulate 
aqueous solutes and act as drug carriers. Niosomes are 
formed by the self assembly of non-ionic amphiphiles in 
aqueous media. The application of heat or physical 
agitation helps the process to attain a closed bilayer 
structure. Their uptake by organs such as the liver and 
spleen make niosomes best suited as drug delivery agents 
in diseases affecting these organs. They are also used in 
targeting cancer cells. Since niosomal antigens are potent 
stimulators of the cellular and humoral immune 
responses they are also useful as adjuvants in vaccine 
delivery. High levels of drugs were found in the target 
location when administered via niosomes compared to 
conventional routes. They have also been used with anti-
inflammatory agents and anti-infective agents. 
PEGylated cationic niosomes have been used for the 
cellular delivery of oligonucleotides. Niosomes improve 
percutaneous passage of 5- fluorouracil (5-FU) through 
human stratum corneum and epidermis, and are non-
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toxic. Niosomes of frusamide have been reported, that 
increased skin permeability and sustained drug levels35. 
Dendrimers 
A generally accepted definition of dendrimer is a 
monodisperse macromolecule with perfectly branched 
regular structure and having at least one branched 
junction at each repeat unit. Dendrimers are a type of 
nanostructure that can be precisely designed and 
manufactured for a wide variety of applications, 
including the treatment of cancer and other diseases. 
Dendrimers carrying different materials an their branches 
can do several things at one time, such as recognizing 
diseased cells, diagnosing diseased states (including cell 
death), drug delivery, reporting location, and reporting 
outcomes of therapy. 
Dendrimers molecule has found use as diagnostic reagent 
for tumour imaging by magnetic resonance imaging and 
as contrast agent; by varying the size and hydrophilicity 
and by combining with tumour targeting antibodies, 
these compounds can be used for a range of specific 
imaging purpose
36
. The topical application of active 
drugs to the eye is the most prescribed route of 
administration for the treatment of various ocular 
disorders. Dendrimers provide unique solutions to 
complex delivery problems for ocular drug delivery. An 
ideal ocular drug delivery system should be non-
irritating, biocompatible, sterile, isotonic and 
biodegradable37. The recent problems for ocular drug 
delivery focus on increasing the residence time of 
pilocarpine in the eye was overcome by using PAMAM 
(polyamidoamine) dendrimers with carboxylic or 
hydroxyl surface groups. These surface modified 
dendrimers were predicted to enhance pilocarpine 
bioavailability38. 
Carbone Nano Tubes  
CNTs have the ability to transport drug molecules, 
proteins and nucleotides. Due to their size and shape, 
carbon nanotubes can enter living cells without causing 
cell death or obvious damage. Molecules can be 
covalently or non-covalently attached to the surface. The 
hollow structure of CNTs allows encapsulation of 
molecules but as yet there are very few examples of this 
for drugs delivery. For biological applications CNTs 
require covalent or non-covalent39-40 fictionalization to 
prevent aggregation and increase their solubility. Several 
drugs have been successfully delivered, including 
amphotericin B41, which is normally insoluble and toxic 
due to its tendency to aggregate. When delivered using 
CNTs there was increased solubility, low aggregation 
(and therefore lower toxicity) and increased anti-fungal 
action. A number of therapeutic applications of CNTs 
have been reported, including boron neutron capture 
therapy (BNCT), inducing immunoresponse, gene and 
siRNA delivery 42. 
Nanopores  
Nanopores designed by Desai and Ferrari (1997), consist 
of wafers with high density of pores (20 nm in diameter). 
The pores allow entry of oxygen, glucose and other 
products like insulin to pass through. However, it does 
not allow immunoglobulin and cells to pass through 
them. Nanopores can be used as devices to protect 
transplanted tissues from the host immune system, at the 
same time, utilizing the benefit of transplantation. βcells 
of pancreas can be enclosed within the nanopore device 
and implanted in the recipient‟s body. This tissue sample 
receives the nutrients from the surrounding tissues and at 
the same time remains undetected by the immune system 
and hence do not get rejected43. This could serve as a 
newer modality of treatment for insulin dependent 
diabetes mellitus44.Nanopores can also be employed in 
DNA sequencing. Branton‟s team at Harvard 
University45 has worked on modified nanopores that 
have the ability to differentiate DNA strands based on 
differences in base pair sequences. Nanopores are also 
being developed with ability to differentiate purines from 
pyrimidines. Further, incorporation of electricity 
conducting electrodes is being designed to improve 
longitudinal resolution for base pair identification 46. 
Such a method could possibly read a thousand bases per 
second per pore. These can be used for low cost high 
through put genome sequencing47 which would be of 
great benefit for application of pharmacogenomics in 
drug development process. 
Microemulsion/Nanoemulsion 
Microemulsions are isotropic, thermodynamically stable 
systems composed of oil, water, and surfactant. 
Thermodynamic stability rather than size, is the defining 
hallmark of a microemulsion, although the droplet sizes 
are still below 100 nm (and many times much smaller). 
Be that as it may, what is critical about microemulsions 
is that, they contain two phases consisting of two 
immiscible liquids that are mixed together and stabilized 
with the aid of a surfactant with or without a co-
surfactant. They may have droplets in the range of 5–100 
nm. The difference between microemulsions and 
emulsions is that, the later are opaque mixtures of two 
immiscible liquids, thermo- dynamically unstable and 
usually require the application of high torque mechanical 
mixing or homogenization to produce dispersed droplets 
in the range of 0.2–25 mm. Both types can be made as 
water-in-oil (w/o) or oil-in-water (o/w). Choice of the 
dispersed and continuous phases for microemulsions 
formulations is based on the hydrophilicity of the model 
drug.  Also, surfactants that have hydrophilic–lipophilic 
balances (HLB) of 3–6 tend to promote the formation of 
w/o microemulsions while those with HLB values of 8–
10 tend to promote the formation of o/w microemulsions. 
It has been reported53 that, the formation and stability of 
microemulsions are dependent on the interfacial tension 
between the dispersed and continuous phases. 
Microemulsion instability can lead to Ostwald ripening 
leading to dissolution of the small droplets with a 
resultant increase in the size of the large droplets, 
therefore, stabilization against Ostwald ripening is very 
critical, this is because, the resultant change in the size of 
the droplets could lead to loss of physical stability of the 
dosage form. Choice of the components of 
microemulsions affects its stability. Safety is also 
another important factor that must be considered during 
component selection. Attwood, 1994 had concluded that, 
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the irritant and toxic properties of some alcohols (1-
butanol and 2-butanol) could limit their potential use. 
Microemulsions have been proposed as drug delivery 
systems to enhance the absorption of drug across 
biological membranes. Some of the advantages of 
microemulsions include (i) Increased solubility and 
stability of drugs (ii) ease and economy of scale-up. 
Some of the disadvantages are; (a) premature 
leakage/release of incorporated drug (b) phase inversion 
(c) Many of the effective surfactants and/or co- 
surfactants do not have a pharmaceutically acceptable 
toxicity profile; and (d) microemulsion systems often 
require development of complex systems that may be 
time consuming49.   
Nanosuspensions 
Nanosuspensions are colloidal dispersions of 
nanoparticles of an insoluble molecule, which are 
stabilized by surfactants. Nanosuspensions can be used 
to maintain these drugs in a preferred crystalline state of 
sufficiently small size for intravenous administration. 
Their advantages are similar to those of nanoemulsions. 
They can also achieve even higher levels of drug loading 
because the drug is in the solid state. Several studies 
have demonstrated the use of nanosuspensions for drug 
delivery with improved efficacy and release50.  
Nanocrystals  
Nanocrystals are aggregates comprising several hundred 
to tens of thousands of atoms that combine into a 
"cluster". Typical sizes of these aggregates are between 
10-400 nm and they exhibit physical and chemical 
properties somewhere between that of bulk solids and 
molecules. By controlling the size and surface area, other 
properties such as bandgap, charge conductivity, 
crystalline structure and melting temperature can be 
altered. The crystals must be stabilized to prevent larger 
aggregates from forming. Nanocrystals are produced by 
nanosonication. First, a nanosuspension is formed by 
high speed stirring, followed by wet milling, high 
pressure homogenisation, nanocrystallisation and spray 
drying to create nanosized crystals. The advantages of 
nanocrystallisation are the ability to solubilise poorly 
soluble drugs, high bioavailability, major decrease in 
dosage volume, and an increase in tolerated dose51. 
Micelles  
Micelles are also spherical lipid nanostructures but they 
do not have a bilayer or inner cavity. The hydrophobic 
ends of the phospholipids point inwards and the 
hydrophilic ends face the outside, forming a spherical 
structure. Reverse micelles have this polarity the 
opposite way. The typical size of micelles for 
pharmaceutical applications ranges from 10-80 nm. 
Compared to liposomes, micelles have a short circulation 
time within the body due to their smaller size. However, 
this gives them the advantage of being able to enter 
tumour cells more easily, because of the EPR effect. 
Micelles can also be made from polymers. Polymeric 
micelles are formed by block- copolymers consisting of 
hydrophilic (e.g. PEG) and hydrophobic monomer units 
with longer hydrophilic blocks and shorter hydrophobic 
blocks. They have a hydrophobic core stabilized by 
hydrophilic units. These micelles are more stable than 
conventional micelles and are preferred for drug delivery 
applications as the circulation time is longer and they 
offer better biodistribution. Lipid-polymer conjugate 
micelles can also be made. They can carry different types 
of chemicals like paclitaxel, diazepam and captothecin. 
They also exhibit good longevity and stability. Micelles 
with improved solubility and intracellular delivery have 
been prepared using PEG-phosphatidylethanolamine 
(PEG-PE) conjugates. Micelles conjugated with 
transferrin can target cancer cells and deliver DNA. 
Similarly folate residues attached to micelles have been 
used to deliver adriamycin to cancer cells.The advantage 
of such agents is enhanced target penetration due to the 
smaller size and easy movement to the target location52-
53. The particle range of different nanotechnology 
techniques are listed in Table 2. 
Table: 2 Particle size range for different nanotech 
techniques: 
S.N. Technique Particle Size 
1 Nanoparticles 10-1000nm 
2 Gold Nanoparticles 5-50nm 
3 Magnetic Nanoparticles  5-500nm 
4 Liposomes 15nm to several nm 
5 Niosomes 20nm to several 
micrometers 
6 Dendrimers 1.5-10nm 
7 Carbon Nano Tubes           Less then 100nm                                        
8 Nanoemulsion 50-1000nm 
9 Nanosuspension 10-1000nm 
10 Nanocrystals 10-400nm 
11 Micelles 10-80nm 
 
CHALLENGES OF NANO DRUG DELIVERY   
Although nanotechnology in drug delivery has been 
successful, as evidenced by some nano drug products in 
the market, not all approaches have met with the same 
success. New nanomaterials being developed come with 
challenges which have to be surmounted. However some 
of the challenges encountered have been and are still 
being tackled by modification of the physicochemical 
characteristics of the nanomaterials to improve on 
properties such as long circulation in the blood, increased 
functional surface area, protection of incorporated drug 
from degradation, crossing of biological barriers and 
site-specific targeting.     
Another challenge of research and development (R&D) 
of nanomaterials for drug delivery is large scale 
production. There is always a need to scale up laboratory 
or pilot technologies for eventual commercialization. A 
number of nano drug delivery technologies may not be 
scalable due to the method and process of production and 
high cost of materials employed. The challenges of 
scaling up include low concentration of nanomaterials, 
agglomeration and the chemistry process – it is easier to 
modify nanomaterials at laboratory scale for improved 
performance than at large scale. Maintaining the size and 
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composition of nanomaterials at large scale is also a 
challenge 54. 
APPLICATION OF NANOTECHNOLOGY  
The importance of nanotechnology in therapeutics and 
the role played by it in combating some of the chronic 
diseases, such as cancer. Areas in drug delivery where 
nanotechnology can make a difference include:  
 Developing systems that improve the solubility 
and bioavailability of hydrophobic drugs. 
 Designing delivery vehicles that can improve 
the circulatory presence of drugs. 
 Eliminating or minimising toxicity.  
 Increasing specificity. 
 Targeting drugs to specific cells or tissues. 
 Improving vaccine adjuvants and delivery. 
 Developing novel nanostructures that can be 
used in specific applications, e.g. ocular, cancer therapy, 
neurology, orthopaedics.  
 Delivery of repaired genes or the replacement of 
incorrect genes is fields in which nanoscale objects could 
be introduced successfully. 
Some Patents of nanotechnology are listed in Table 3.
 
Table: 3 List of Some Patents on Nanotechnology 
S No. Patent No Filing 
Date/Publication Date 
Applicant  Title 
1 W02010010431A1 Apr 2, 2009/ Jan 28, 
2010 
NIPER Self-nano-emulsifying curcuminoids 
composition with enhanced 
bioavailability 
2 W02010106191A1 Mar 22, 2010/ Sep 23, 
2010 
Bioxtract S.A Pharmaceutical composition presenting 
anti-inflammatory properties 
3 US20030165438 Jun 29, 2002/ Sep 4, 
2003 
Dariush Behnam Water-free ubichinon concentrate 
4 US20040258744 Oct 23, 2003/ Dec 23, 
2004 
Counsell 
Raymond E.  
Surface modified lipoprotein-like oil in 
water emulsion having lipophilic core 
surrounded by monolayer of amphiphilic 
or polar lipids; polyoxyethylene glycol 
linked lipid and (choles)terol; 
radioactive or stable, synthetic 
polyhalogenated triglycerides as contrast 
agents; radiographic imaging 




Emulsion with hydrophilic, hydrophobic 
phase ; reacted in presence of catalyst; 
anticancer agents, aids, antiarthritic 
agents, antidiabetic agents, analgesics 
6 US20080255247 Nov 22, 2006/ Oct 16, 
2008 
Nestec S.A. Droplets exhibit a nano-sized self-
assembled structurization, a diameter 
size of 0.5 to 200 nm; a lipophilic 
additive, an active element; solubilizing 
nutrients, drugs, aromas or chemicals 
 
CONCLUSION 
Nanotechnology offers the ability to build large numbers 
of products that are incredibly powerful by today's 
standards. This possibility creates both opportunity and 
risk. It would be difficult to deny the potential benefits of 
nanotechnology and stop development of research 
related to it since it has already begun to penetrate many 
different fields of research. However, nanotechnology 
can be developed using guidelines to insure that the 
technology does not become too potentially harmful. 
Humans have the potential to live healthier lives in the 
near future due to the innovations of nanotechnology. 
Like this disease diagnosis, prevention and treatment of 
disease, better drug delivery system with minimal side 
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